BXP vs. PRSR, GROW, DX, PINE, MGP, WPC, SOHO, LMI, ADVT, and SAGA
Should you be buying Beximco Pharmaceuticals stock or one of its competitors? The main competitors of Beximco Pharmaceuticals include Prs Reit (PRSR), Molten Ventures (GROW), DX (Group) (DX), Pinewood Technologies Group (PINE), Medica Group (MGP), Witan Pacific Investment Trust PLC (WPC.L) (WPC), Triple Point Social Housing REIT (SOHO), Lonmin (LMI), AdvancedAdvT (ADVT), and Saga (SAGA). These companies are all part of the "trading" industry.
Beximco Pharmaceuticals vs.
Beximco Pharmaceuticals (LON:BXP) and Prs Reit (LON:PRSR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations.
1.7% of Beximco Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.6% of Prs Reit shares are owned by institutional investors. 7.6% of Prs Reit shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Prs Reit had 1 more articles in the media than Beximco Pharmaceuticals. MarketBeat recorded 3 mentions for Prs Reit and 2 mentions for Beximco Pharmaceuticals. Prs Reit's average media sentiment score of 0.25 beat Beximco Pharmaceuticals' score of 0.02 indicating that Prs Reit is being referred to more favorably in the news media.
Beximco Pharmaceuticals has higher revenue and earnings than Prs Reit. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Prs Reit, indicating that it is currently the more affordable of the two stocks.
Prs Reit has a net margin of 108.08% compared to Beximco Pharmaceuticals' net margin of 12.37%. Beximco Pharmaceuticals' return on equity of 10.99% beat Prs Reit's return on equity.
Prs Reit has a consensus target price of GBX 120, suggesting a potential upside of 11.52%. Given Prs Reit's stronger consensus rating and higher probable upside, analysts plainly believe Prs Reit is more favorable than Beximco Pharmaceuticals.
Beximco Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Prs Reit has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.
Beximco Pharmaceuticals received 23 more outperform votes than Prs Reit when rated by MarketBeat users. Likewise, 64.67% of users gave Beximco Pharmaceuticals an outperform vote while only 50.00% of users gave Prs Reit an outperform vote.
Beximco Pharmaceuticals pays an annual dividend of GBX 3 per share and has a dividend yield of 7.7%. Prs Reit pays an annual dividend of GBX 4 per share and has a dividend yield of 3.7%. Beximco Pharmaceuticals pays out 3,750.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Prs Reit pays out 3,636.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Summary
Prs Reit beats Beximco Pharmaceuticals on 12 of the 20 factors compared between the two stocks.
Get Beximco Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beximco Pharmaceuticals Competitors List
Related Companies and Tools
This page (LON:BXP) was last updated on 1/21/2025 by MarketBeat.com Staff
